DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pridopidine
Pridopidine
Stems for Nonproprietary Drug Names
Copyrighted Material
Pridopidine for the Treatment of Motor Function in Patients with Huntington’S Disease (Mermaihd): a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial
Etiology and Pathogenesis of Parkinson's Disease
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Pridopidine in Huntington Disease Pridopidine Is Currently in Development for Huntington Disease (HD)
Comparative in Vivo Pharmacology of Dopidines a Novel Class of Compounds Discovered by Phenotypic Screening
April Through June 2014
Prokineticin 2 Signaling: Genetic Regulation and Preclinical Assessment in Rodent Models of Parkinsonism Jie Luo Iowa State University
(Propyl)Amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease S
AHRQ Healthcare Horizon Scanning System – Status Update Horizon
WHO Drug Information Vol
Profile of Pridopidine and Its Potential in the Treatment of Huntington Disease: the Evidence to Date
Known Drugs Identified by Structure-Based Virtual Screening
[11C]PB212 As a Radioligand for Imaging Sigma-1 Receptors Using PET
Pridopidine in the Pharmacological Treatment of Huntington's Disease
ABSTRACTID TITLE AUTHORS 113502 Effect of PGE Inhibition on Striatal Neuroinflammation in 6-OHDA Lesion Temitope Adu; Musa Maban
The Impact of Psychostimulant Administration During Development on Adult Brain Functions Controlling Motivation, Impulsivity and Cognition
Top View
Managing Movements
Pridopidine Stabilizes Mushroom Spines in Mouse Models Of
Development of Novel Serotonin 5-HT6 and Dopamine D2 Receptor
Neurodegeneration Product Guide | Edition 2
Dual-Specificity Phosphatases in Mental and Neurological Disorders
Ep 3590512 A1
Mental Health in Adulthood
Novel Norbornane Derivatives As Potential Neuroprotective Agents
Valstybinės Vaistų Kontrolės Tarnybos Prie Lietuvos Respublikos Sveikatos Apsaugos Ministerijos Viršininko Įsakymas
New Avenues for the Treatment of Huntington's Disease
Mcgarry Et Al., 2020
Dopamine and Huntington's Disease
Pridopidine (Huntexil) for Huntington's Disease
Dysregulation of Corticostriatal Connectivity in Huntington's Disease
(12) Patent Application Publication (10) Pub. No.: US 2011/0206782 A1 Zhang (43) Pub
專利條例第 20 條發表的指定專利申請記錄請求 Requests to Record Designated Patent Applications Published Under Section 20 of the Patents Ordinance
In Vivo Pharmacology of the Dopaminergic Stabilizer Pridopidine
On Chorea, George Huntington and Has Several Functions in Human Neurons
IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications In
Model Membranes for Drug- Membrane Interaction Studies
Neuronal Signaling
2 Receptor and Its Role in Cancer with Focus on a Multitarget Directed Ligand (MTDL) Approach
Clinical Study Protocol with Amendment 05 Study TV7820-CNS-20002
Acknowledgements
Antidepressant-Like Effect of the Norepinephrine-Dopamine Reuptake Inhibitor Bupropion in a Mouse Model of Huntington’S Disease with Dopaminergic Dysfunction
2018 Medicines in Development for Neurological Disorders a Report on Disorders of the Brain, Spinal Cord and Nerves
New Product Evaluations - a Resource for Medicines Management
Early Pridopidine Treatment Improves Behavioral and Transcriptional Deficits in YAC128 Huntington Disease Mice
Pridopidine: Overview of Pharmacology and Rationale for Its Use in Huntington's Disease
(Propyl)Amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease S
Antipsychotics for Treatment of Delirium in Hospitalised Non-ICU Patients
In Vitro and in Vivo Identification of New Domperidone Metabolites by LC
OUTCOMES REPORT 2020 Outcomes Report 2020
Dopamine Receptor
Chorea/Morbus Huntington
The Sigma-1 Receptor Mediates Pridopidine Rescue Of
Horizon Scanning Status Report, March 2021, Volume 3, Issue 1
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
31ST ECNP CONGRESS 6-9 OCTOBER 2018 BARCELONA the Future of CNS Treatments